Catalog No.S1941 Synonyms: MK-421 Maleate
Molecular Weight(MW): 492.52
Enalapril Maleate is an angiotensin-converting enzyme (ACE) inhibitor, used in the treatment of hypertension, diabetic nephropathy, and chronic heart failure.
Purity & Quality Control
Choose Selective RAAS Inhibitors
|Description||Enalapril Maleate is an angiotensin-converting enzyme (ACE) inhibitor, used in the treatment of hypertension, diabetic nephropathy, and chronic heart failure.|
Enalapril is rapidly converted by ester hydrolysis to enalaprilat, a potent ACE inhibitor; Enalapril itself is only a weak ACE inhibitor. Enalapril lowers peripheral vascular resistance without causing an increase in heart rate. 
|In vivo||Enalapril treatment abolishes the deleterious effects of eNOS deficiency on blood pressure (BP), atherosclerosis, and kidney dysfunction in nnee mice.  Enalapril causes a dose-dependent increase in fore limb strength in the mdx mouse. Enalapril causes a dose-dependent reduction of superoxide anion production in tibialis anterior muscle of the mdx mouse as observed by dihydroethidium staining. Enalapril (5 mg/kg) reduces the area of muscle necrosis in both gastrocnemious muscle and diaphragm, without significant effect on non-muscle area.  Enalapril Maleate results in significant increases in kidney weight and in concentrations of urinary albumin, N-acetyl-fl-d-glucosamidase (NAG) and serum ET-1 in streptozotocin (STZ)-induced diabetic (STZ-DM) rats as compared with the non-diabetic rats, and the concentration of ET-1 in the kidneys tended to be increased. Enalapril Maleate results in increased mesangial cell proliferation, matrix expansion and enlarged mesangial area in the kidney of the diabetic rats. Enalapril Maleate reduces increased concentrations of urinary albumin and NAG in the STZ-DM rats to the control values with a slight improvement in the electron microscopic changes.|
|In vitro||DMSO||99 mg/mL (201.0 mM)|
|Ethanol||4 mg/mL (8.12 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03265574||Unknown status||Drug: Enalapril||Breast Cancer||South Tees Hospitals NHS Foundation Trust|Newcastle University|University of Durham|Newcastle-upon-Tyne Hospitals NHS Trust||September 1 2017||Phase 3|
|NCT03051282||Recruiting||Drug: Enalapril||Healthy Volunteers||University of Michigan||April 1 2017||Phase 4|
|NCT03460366||Recruiting||Drug: Enalapril||Obesity Morbid||Norwegian University of Science and Technology|St. Olavs Hospital|Volvat Medisinsk Senter Stokkan|Namsos Hospital|Alesund Hospital||November 2 2016||--|
|NCT02654678||Unknown status||Drug: Enalapril Orodispersible Minitablet||Heart Failure|Dilated Cardiomyopathy|Congenital Heart Disease||Ethicare GmbH||March 2016||Phase 2|Phase 3|
|NCT02652728||Unknown status||Drug: Enalapril Orodispersible Minitablet||Heart Failure|Dilated Cardiomyopathy||Ethicare GmbH||January 2016||Phase 2|Phase 3|
|NCT02652741||Unknown status||Drug: Enalapril Orodispersible Minitablet||Heart Failure|Congenital Heart Disease||Ethicare GmbH||January 2016||Phase 2|Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.